These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 23495686)

  • 1. Targeting vascular (endothelial) dysfunction.
    Daiber A; Steven S; Weber A; Shuvaev VV; Muzykantov VR; Laher I; Li H; Lamas S; Münzel T
    Br J Pharmacol; 2017 Jun; 174(12):1591-1619. PubMed ID: 27187006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploiting the Pleiotropic Antioxidant Effects of Established Drugs in Cardiovascular Disease.
    Steven S; Münzel T; Daiber A
    Int J Mol Sci; 2015 Aug; 16(8):18185-223. PubMed ID: 26251902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin-polynitroxides: synthesis and preliminary evaluation as cardiovascular EPR/MR imaging probes and extracellular space-targeted antioxidants.
    Kleschyov AL; Sen' V; Golubev V; Münnemann K; Hinderberger D; Lackner KJ; Weber S; Terekhov M; Schreiber LM; Münzel T
    Eur J Med Chem; 2012 Dec; 58():265-71. PubMed ID: 23127990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute effect of standard heparin versus low molecular weight heparin on oxidative stress and inflammation in hemodialysis patients.
    Poyrazoglu OK; Dogukan A; Yalniz M; Seckin D; Gunal AL
    Ren Fail; 2006; 28(8):723-7. PubMed ID: 17162433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Sodium iodoheparinate; its value in the treatment of cardiovascular diseases].
    Warembourg H; Delomez M
    Lille Med; 1967 Feb; 12(2):Suppl:129-33. PubMed ID: 5623383
    [No Abstract]   [Full Text] [Related]  

  • 6. [Anticoagulant therapy in cardiovascular diseases. I. Thrombus formation and anticoagulants].
    Latallo ZS; Malanowicz W
    Kardiol Pol; 1970; 13(4):351-8. PubMed ID: 4099312
    [No Abstract]   [Full Text] [Related]  

  • 7. Heparin-polynitroxide derivatives: a platform for new diagnostic and therapeutic agents in cardiovascular disease?
    Kleschyov AL; Sen' VD
    Future Med Chem; 2013 Mar; 5(4):385-8. PubMed ID: 23495686
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacological approaches to the treatment of oxidative stress-induced cardiovascular dysfunctions.
    Zamora PL; Villamena FA
    Future Med Chem; 2013 Mar; 5(4):465-78. PubMed ID: 23495692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic applications of PI3K inhibitors in cardiovascular diseases.
    Ghigo A; Morello F; Perino A; Hirsch E
    Future Med Chem; 2013 Mar; 5(4):479-92. PubMed ID: 23495693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Update on anticoagulant therapy].
    Gensini GF; Falciani M; Dilaghi B; Poli D
    Cardiologia; 1999 Dec; 44 Suppl 1(Pt 2):673-80. PubMed ID: 12497803
    [No Abstract]   [Full Text] [Related]  

  • 11. [-Anticoagulant drugs-].
    Gulba DC
    Herz; 1996 Feb; 21(1):12-27. PubMed ID: 8647576
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.